This startup produces nutrient-dense food ingredients by upcycling residual agricultural materials, utilizing methods such as fiber extraction and blending to enhance nutritional content. Their offerings, including multifunctional oat and corn fibers, enable food manufacturers to improve product functionality while maintaining flavor and quality.

The startup develops a ventricular system for managing cerebrospinal fluid in patients with hydrocephalus, specifically targeting complications from non-flowing shunts. This neurotherapeutic device enhances neurocritical care during repeat revision brain surgeries, improving patient outcomes by preventing brain damage associated with fluid mismanagement.

CardioMech develops a catheter-based device that utilizes artificial chords to reduce mitral regurgitation, a condition characterized by the backward flow of blood across the mitral valve. This technology offers a less invasive alternative to open-heart surgery for patients with structural heart disease, potentially improving outcomes and reducing recovery times.

Clozex Medical develops skin closure devices utilizing interlaced locking technology to securely close surgical incisions and traumatic lacerations. Their products are clinically proven to minimize scarring, providing a simple and effective solution for wound management.

Aknext provides an AI-powered content generation platform that enables users to create high-quality written and visual content rapidly, utilizing built-in generative algorithms and customizable templates. This technology addresses the challenge of time-consuming content creation processes, allowing businesses to produce engaging material for various applications, including social media, blogs, and marketing campaigns, significantly faster and at reduced costs.

Destinus develops autonomous flight systems capable of operating across the entire speed spectrum, from subsonic to hypersonic, utilizing advanced airframe designs and turbojet engines. The company addresses the need for efficient and rapid transportation solutions for both civilian and defense applications, enhancing global connectivity and exploration.

Enalare Therapeutics is developing ENA-001, a novel therapeutic agent designed to stimulate breathing in patients experiencing acute respiratory depression due to drug overdoses, post-operative complications, or apnea of prematurity. This new chemical entity aims to provide effective treatment options for healthcare providers managing life-threatening respiratory conditions.

This startup produces wine and spirits by synthesizing flavor, aroma, and color molecules from plants and animals, eliminating the need for grapes, yeast, and fermentation. By using significantly less water, the company offers a sustainable alternative to traditional winemaking, addressing the environmental impact of grape cultivation.

Halo Industries develops proprietary laser-based hardware for silicon carbide (SiC) wafering, achieving superior wafer-per-millimeter yield while minimizing material stress and kerf loss. The technology enhances manufacturing efficiency by reducing material, energy, and water consumption compared to traditional wafering methods.

The startup has developed an AI clinical decision support platform that continuously monitors patient health metrics in real time. This technology enables healthcare providers and caregivers to promptly identify and respond to clinical issues, improving patient outcomes and health management.

The startup is developing a new class of flexible therapeutics and diagnostics that can bind multiple targets simultaneously, specifically for oncology, metabolic diseases, and neurodegenerative disorders. This technology enables early disease diagnosis and targeted treatment, improving patient outcomes through enhanced therapeutic precision.

Livly offers a technology-driven platform that integrates property management tasks, including rent payments, maintenance requests, and resident engagement, into a single mobile application. This solution enhances operational efficiency and resident satisfaction for property operators and management companies by streamlining communication and reducing administrative overhead.

This healthcare company formulates probiotics, vitamins, supplements, and skincare products using high-quality ingredients developed in collaboration with scientists and healthcare professionals. Their offerings include clinically tested sleep aids and brain health therapeutics, providing customers with effective natural solutions to enhance overall wellness.

Momentus provides satellite buses and in-space transportation services, enabling efficient deployment and operation of satellites in low Earth orbit. The company addresses the logistical challenges of satellite delivery and in-orbit servicing, facilitating enhanced satellite functionality and mission success.

The startup is developing a pharmaceutical platform that focuses on non-opioid pain therapeutics, featuring four drug candidates targeting both acute and chronic pain. This platform provides patients with effective alternatives to opioids, addressing the need for viable analgesics in both hospital and retail settings.

NobleAI provides a cloud-based platform that utilizes Science-Based AI to accelerate the development of materials and chemicals by enabling rapid formulation and optimization. The platform addresses the lengthy and costly process of product innovation, allowing companies to create safe and sustainable products in minutes rather than months.

ONDO Systems offers application software designed for senior living and childcare services, enhancing operational efficiency and care management through improved communication and coordination among caregivers, families, and service providers. The platform addresses challenges in resource allocation and care quality, ensuring better outcomes for both residents and staff.

PostProcess Technologies provides fully automated post‑processing platforms for additive manufacturing, handling support removal, resin cleaning, surface finishing, and powder depowdering across FDM, PolyJet, SLA/DLP, wax, and powder‑based systems. The systems combine robotic handling, ultrasonic or fluid cleaning, abrasive‑flow finishing, and conveyor‑driven depowdering with PLC‑based control and open API integration for repeatable, traceable high‑volume production.

ReliefBand Technologies develops FDA-cleared wearable devices that utilize patented neuromodulation technology to deliver electrical pulses to the median nerve on the wrist, effectively reducing nausea and vomiting. The devices provide a drug-free solution for various conditions, including motion sickness, morning sickness, and chemotherapy-related nausea, offering relief within minutes without side effects.

Scioto develops an Activated Bacterial Therapeutics platform that enhances the delivery and efficacy of live bacterial therapeutics by leveraging biofilm formation to optimize gut health. Their technology specifically targets gastrointestinal disorders and autism spectrum disorder, addressing unmet medical needs through improved therapeutic interactions within the gut-brain axis.

Utilizes a proprietary Click Activated Protodrugs Against Cancer (CAPAC®) platform to deliver cancer therapies by separating tumor-targeting binders from inert payloads, which are activated through in-vivo click chemistry at the tumor site. This approach increases the concentration of active drugs or radioisotopes at tumors while reducing systemic toxicity, improving treatment efficacy for patients with limited options.

The startup has developed a superficial radiotherapy technology that provides a non-invasive treatment option for non-melanoma skin cancer. This method allows physicians to deliver effective radiation therapy in their offices, minimizing the side effects associated with traditional surgical treatments.

The startup operates a plasma collection service that facilitates the donation of plasma from volunteers for use in life-saving therapies. This process provides essential treatment for patients suffering from rare chronic diseases, such as hereditary angioedema, by ensuring a steady supply of high-quality plasma.

Virion Therapeutics is a clinical-stage biopharmaceutical company developing T cell-based immunotherapies that utilize genetically encoded checkpoint modifiers to enhance CD8+ T cell responses against virally-associated cancers and chronic infectious diseases. Their approach aims to improve clinical outcomes and survival rates in patients, with ongoing human studies for their lead program targeting chronic HBV.